Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 18/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453830 | 0.87 | CCR5 (0.51) | CCR5KCNH2ARG1PRCP | |
| SCHEMBL5451917 | 0.87 | CCR5 (0.51) | CCR5KCNH2ARG1PRCP | |
| SCHEMBL5466311 | 0.82 | CCR5 (0.43) | CCR5 | |
| SCHEMBL13687240 | 0.80 | CCR5 (0.55) | CCR5KCNH2ARG1PRCP | |
| SCHEMBL5466360 | 0.79 | CCR5 (0.40) | CCR5 | |
| SCHEMBL5466362 | 0.79 | CCR5 (0.40) | CCR5 | |
| SCHEMBL7240275 | 0.78 | CCR5 (0.53) | CCR5KCNH2 | |
| SCHEMBL7240270 | 0.78 | CCR5 (0.53) | CCR5KCNH2 | |
| SCHEMBL7114293 | 0.78 | CCR5 (0.55) | CCR5KCNH2 | |
| SCHEMBL7117992 | 0.78 | CCR5 (0.61) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | claimed |
| US-6511994-B2 | For prophylaxis and therapy of infection by HIV and the treatment of AIDS | MERCK & CO., INC. | 2003-01-28 | — | — | US | claimed |
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | claimed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-7153868-B2 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. | 2006-12-26 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| US-6511994-B2 | For prophylaxis and therapy of infection by HIV and the treatment of AIDS | MERCK & CO., INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | CCR5, CXCR3, CXCR1 | CCR5 1/4885KCNH2 3930/4885ARG1 188/4885 |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | KCNH3, KCNH2, KCNK3 | CCR5 710/4885KCNH2 2/4885ARG1 1173/4885 |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | TACR2, KCNK3, KCNH3 | CCR5 1040/4885KCNH2 5/4885ARG1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.